-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $64

Benzinga·04/28/2025 10:54:56
Listen to the news
Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Buy rating and announces Price Target of $64.